Effectiveness of Intraoperative Cell Salvage in Aseptic Revision Total Hip Arthroplasty.

Effectiveness of Intraoperative Cell Salvage in Aseptic Revision Total Hip Arthroplasty: a Single-center Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05237830

Enrollment

140

Registered

2022-02-14

Start date

2011-01-01

Completion date

2022-01-31

Last updated

2022-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Revision of Total Hip Arthroplasty

Brief summary

Intraoperative cell salvage is an important measure of patient blood management but its effectiveness in patients undergoing revision total hip arthroplasty remains unclear. Over the last decade, we have used intraoperative cell salvage systematically in this group of patients. However, since the use of cell salvage has a cost and requires additional resources, we decided to retrospectively investigate its usefulness in this particular indication.

Interventions

PROCEDUREUse of Cell Salvage in revision of total hip arthroplasty

The effective use of the cell saver was defined as the ability to re-transfuse at least 125 mL of re-suspended red blood cells with a hematocrit of 60 %.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Eligible patients were adults undergoing elective aseptic revision of hip arthroplasty at the department of orthopedic surgery of the University Hospital of Liege between 01 January 2011 and 31 December 2020.

Exclusion criteria

* Patients undergoing revision for infection or with local malignancies were excluded from this study.

Design outcomes

Primary

Measure	Time frame	Description
Cell savage use	during the surgical procedure	The primary outcome was the proportion of patients in whom the cell saver was effectively used (%)

Secondary

Measure	Time frame	Description
Re-infused	during the surgical procedure	Total volume of re-suspended blood re-infused (mL)
Hemoglobin	during the surgical procedure	Post-operative hemoglobin level (g/dL)
Allogenic Transfusion	7 days	The need for allogenic blood transfusion (unit)
Aspirated blood	during the surgical procedure	The total volume of blood aspirated into the reservoir (mL)
Fluid	during the surgical procedure	The total amount of fluid infused (mL)

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026